, /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately.
Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accounting, governance, and audit oversight, with extensive experience advising public and private companies on complex regulatory and financial matters.
"We are pleased to welcome Shlomo as Chairman of the Board," said Moshe Mizrahy, Chief Executive Officer. "His deep expertise in corporate governance, financial oversight, and regulatory matters, combined with his extensive leadership experience, will be invaluable as we continue to execute our strategic priorities and drive long-term shareholder value."
"On behalf of the Board and management team, we thank Michael Anghel for his many years of commitment and service to InMode and wish him all the best going forward," Mizrahy concluded.
At the same time, InMode announced the appointment of Moshik Itzkovich as Chief Financial Officer. Moshik has held senior finance roles at InMode and was previously Senior Vice President of Finance. He replaces Yair Malca, who stepped down earlier this month and will serve as a consultant at least through the Company's Annual General Meeting to ensure a smooth transition.
"Having partnered closely with Yair over the last three years, Moshik brings continuity, financial expertise, and strategic insight to this role," said Moshe Mizrahy, Chief Executive Officer. "We are confident he is well positioned to build on our strong financial foundation and support the Company's long-term objectives."
"We thank Yair for his many years of exceptional service. His leadership and contributions have been instrumental to our success, and he played a key role in our transition to a publicly traded Company. He leaves InMode with a very strong balance sheet and solid operational and financial foundations in place for his successor. We are grateful for his lasting impact on the Company," Mizrahy concluded.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the actual amount of share repurchases made by the Company, if any. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2026, and our subsequent public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
[email protected]
Logo - https://mma.prnewswire.com/media/1064477/5978883/InMode_Logo.jpg
InMode Ltd. remains a global leader in minimally-invasive aesthetics, with proprietary RF and laser technologies and a strong international growth trajectory. I maintain a Strong Buy rating for INMD, citing undervaluation, robust free cash flow, a fortress balance sheet, and aggressive share repurchases. U.S. market saturation and sales execution remain challenges, but leadership changes and new product launches are driving positive cultural and operational shifts.
On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant (IMVT +2.13%), an estimated $24.53 million trade based on quarterly average pricing.
Logos bought 1,100,000 additional shares of Immunovant, a transaction estimated at $24.5 million based on average quarterly closing prices.The full position grew by roughly $6.1 million in total value over the quarter, reflecting both the new shares and price movement in the stock.Logos finished the quarter holding 1,375,000 Immunovant shares, valued at roughly $34.95 million which represents 2.11% of the fund’s AUM, placing it outside the fund’s top five holdingsWhat happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Logos Global Management LP increased its position in Immunovant by 1,100,000 shares during the fourth quarter of 2025. The estimated transaction value was $24.4 million, based on the average closing price in the quarter. The value of the stake at quarter-end rose by $6.1 million, a figure that includes both trading and market price effects.
What else to knowAfter the buy Immunovant accounts for 2.11% of the fund’s 13F assets under management (AUM)Top holdings after the filing:NASDAQ:RVMD: $238.50 million (14.4% of AUM)NASDAQ:PRAX: $110.53 million (6.7% of AUM)NASDAQ:IDYA: $108.03 million (6.5% of AUM)NASDAQ:OLMA: $80.22 million (4.9% of AUM)NASDAQ:CDTX: $68.48 million (4.1% of AUM)As of March 13 2026, shares of Immunovant were priced at $24.72, up 29.3% over the past year and outperforming the S&P 500 by 10.58%.Company OverviewMetricValuePrice (as of market close 3/13/26)$24.70Market Capitalization$5.03 billionNet Income (TTM)($464.20 million)1-Year Price Change29.24%Company SnapshotImmunovant is a subsidiary of Roivant Sciences (NASDAQ: ROIV) focused on monoclonal antibody therapeutics for autoimmune diseases.What this transaction means for investorsIts lead candidate, batoclimab, has completed Phase III trials in myasthenia gravis and is in ongoing Phase III trials for thyroid eye disease, with results expected in the first half of 2026.The company has no approved products yet — revenue depends entirely on successful clinical and regulatory outcomes.Immunovant is advancing batoclimab across multiple autoimmune indications, with no approved products yet and a regulatory path that hinges on ongoing Phase III outcomes.
What This Transaction Means for InvestorsLogos Global Management is a San Francisco-based, healthcare-focused hedge fund running a concentrated, research-driven book in life sciences and biotech. This isn't a generalist fund dipping into the sector — it's the kind of firm that does deep scientific and regulatory diligence before sizing up a position.
The Immunovant buy is notable for its scale. Logos nearly quintupled its stake, adding 1.1 million shares for an estimated $24.5 million and bringing its total to roughly $35 million. That's a meaningful commitment: Immunovant now sits at about 2% of AUM, up from 0.4% — a shift that carries real weight in a concentrated book.
For individual investors, a move like this from a specialist healthcare fund is worth treating as a research prompt rather than a buy signal. Clinical-stage biotech carries real binary risk, and institutional conviction here is usually the product of diligence retail investors don't have direct access to. The more useful takeaway is simply that a fund that lives in this space saw enough to add aggressively — why exactly, and how it fits their broader strategy, is hard to know without explicit statements from them. What investors can watch is the batoclimab thyroid eye disease readout, with topline data from both Phase 3 TED studies expected concurrently in the first half of 2026. That's the next concrete event that will shape Immunovant's regulatory path.
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy.
A woman gets her eyes tested in Los Angeles, California September 11, 2014. REUTERS/Mario Anzuoni/File photo Purchase Licensing Rights, opens new tab
CompaniesApril 2 (Reuters) - Immunovant (IMVT.O), opens new tab said on Thursday that its therapy failed to reduce eye bulging when tested in patients with moderate-to-severe thyroid eye disease in two late-stage studies.
Shares of the company were down 4.8% at $23.89.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The results do not support further progress in thyroid eye disease, said Matt Gline CEO of Roivant (ROIV.O), opens new tab, Immunovant's parent company, during a call with analysts.
The studies were testing its experimental therapy batoclimab in the autoimmune disorder that commonly causes proptosis or eye bulging and eye irritation. In severe cases it can also lead to double vision or vision loss.
The company said the studies failed to meet the main goal of an at least 2 millimeter reduction in eye bulging after 24 weeks, following 12 weeks of high-dose and 12 weeks of low-dose batoclimab treatment.
Batoclimab is designed to help the body clear harmful antibodies by blocking a protein that normally keeps them in circulation.
Safety results were consistent with previous findings, Immunovant said.
Immunovant plans to focus future development on its other experimental therapy IMVT-1402, across multiple autoimmune diseases, and said batoclimab for thyroid eye disease is not a key focus area.
The company intends to review future plans for the development of batoclimab with its partner HanAll Biopharma and provide an update on the program at a future date.
On Monday, Viridian Therapeutics' (VRDN.O), opens new tab experimental treatment for thyroid eye disease lagged rivals in efficacy in a late-stage study.
Reporting by Sneha S K in Bengaluru; Editing by Nivedita Bhattacharjee and Shailesh Kuber
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for batoclimab in thyroid eye disease (TED), which failed to meet its primary endpoint.
Brepocitinib expands into lichen planopilaris Matt Gline, CEO of Roivant Sciences, said the companies are moving with “urgency” to broaden the potential of brepocitinib across multiple indications, focusing on orphan immunology diseases with high unmet need, mechanistic alignment with JAK1/TYK2 inhibition, and some level of clinical proof-of-concept.
Gline highlighted Priovant’s existing brepocitinib portfolio, including dermatomyositis (with a PDUFA date in the third quarter), non-infectious uveitis (Phase 3 topline data expected in the back half of the year), and cutaneous sarcoidosis (Phase 3 study planned to start in the second half of the year). He announced LPP as a fourth program, with a combined Phase 2b/3 study that he said began last month and is now underway.
Executives described LPP as a severe inflammatory scalp disorder that can cause scarring and generally irreversible hair loss. Gline said symptoms can include “itch, burning, redness, scaling,” and in many cases “intensely painful” disease. He emphasized there are no FDA-approved therapies and said patients often require chronic, aggressive multi-drug regimens with limited efficacy and poor tolerability. Gline estimated the condition may have “up to 100,000 U.S. patients,” calling it a “large orphan size.”
Ben Zimmer, CEO of Priovant Therapeutics, added that LPP is associated with “an increased risk of many severe comorbidities, including both skin cancer and other autoimmune diseases.” He said many off-label treatments are tried but are often discontinued due to tolerability and limited benefit.
Rationale: TH1-driven biology and existing proof-of-concept Zimmer said Priovant believes LPP biology aligns with brepocitinib’s mechanism, describing LPP as “driven primarily by TH1 polarized T cell aberrant behavior.” He pointed to interferon-gamma and IL-12 as critical TH1 pathway cytokines and said a JAK1/TYK2 inhibitor is positioned to suppress signaling for both.
Zimmer also cited “case reports and investigator-initiated trials” involving JAK1 and TYK2 inhibitors as supportive clinical validation for the mechanism. He discussed a small, investigator-initiated, placebo-controlled trial of brepocitinib at Mount Sinai that used the LPPAI endpoint, which he characterized as noisy and not preferred by clinicians. While cautioning against overinterpreting the small dataset, he said the treated arm “clearly” improved over time.
Zimmer said biomarker data from that study was especially compelling, pointing to effects on “multiple markers of TH1-driven disease activity,” including interferon-gamma, IL-12, and chemokines such as CCL5.
Trial design: combined Phase 2b/3 with endpoint refinement Gline said the LPP program is designed to function as a “straight to registrational” approach. The study includes a 72-patient Phase 2b portion, followed by a seamless transition into a Phase 3 portion expected to enroll approximately 270 patients, with a sample size re-estimation after Phase 2b. He said the structure is intended to support endpoint validation and regulatory alignment while maintaining development speed, but the company is “not ready to guide today” on enrollment timelines.
In Q&A, management described replacing LPPAI with more defined measures. Zimmer said LPPAI lacks standardized definitions for symptom scoring, contributing to variability. Priovant plans to use an Investigator’s Global Assessment (IGA) that measures erythema and scale with defined criteria, along with secondary endpoints evaluating symptoms such as pain and itch via numeric rating scales.
Zimmer said Priovant’s “base case” assumption is that the Phase 3 primary endpoint will be “IGA zero/one with two-point reduction,” while acknowledging the Phase 2b portion is meant to help understand endpoint behavior in a new indication. He added that the company plans to “wash patients out of background meds ahead of the enrollment quite aggressively,” consistent with other Priovant trials.
Batoclimab Phase 3 TED miss; read-through to Graves’ discussed Gline also addressed Phase 3 TED results for batoclimab from Immunovant (NASDAQ:IMVT), describing the failure to meet the primary endpoint (a ≥2 mm proptosis responder rate) as “obviously disappointing.” He noted batoclimab had shown success in an earlier Phase 2 TED study but said this Phase 3 outcome does not support continued development in TED.
Gline emphasized that Immunovant’s future development focus is on IMVT-1402 rather than batoclimab, describing the TED readout as “effectively the last study to read out from the first generation program.” He said the TED trial design included 12 weeks of high-dose batoclimab followed by 12 weeks of lower dose, and he repeatedly pointed to better performance during the higher-dose period. Across endpoints, he said outcomes “got worse as you went from week 12 to week 24” after the dose step-down, which he framed as supportive of the importance of deeper IgG suppression.
In a pooled subset of about 20 hyperthyroid patients across the two studies, Gline reported a 75% mean IgG reduction and an 80% responder rate using the same thyroid hormone normalization definition the company used in a Phase 2 Graves’ disease study. He said the responder rate declined after 24 weeks as IgG suppression lessened, and he suggested the pattern reinforces the concept that “the deeper you can get IgG lower, the better you’re gonna do” in Graves’ disease.
Gline said hyperthyroid patients in the TED studies appeared to do “somewhat better” than the overall population on proptosis outcomes. He also noted that anti-thyroid drug doses were required to remain stable throughout the TED studies, limiting conclusions about dose reduction in clinical practice.
Looking ahead, Gline said the company expects both ongoing Graves’ studies with IMVT-1402 to read out next year and characterized enrollment as “generally going well.”
About Immunovant (NASDAQ:IMVT) Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.
The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.
Further Reading Five stocks we like better than Immunovant
Key Takeaways Immunovant's phase III GO trials of batoclimab in TED miss their primary endpoints.IMVT shares fell 2.4% on April 2 following the disappointing trial results.Batoclimab showed consistent safety and better proptosis improvement in the high-dose phase. Immunovant (IMVT - Free Report) reported top-line results from two phase III studies, known as the GO trials, evaluating batoclimab as an investigational treatment for adult patients with active, moderate-to-severe thyroid eye disease (TED). Both studies failed to achieve their primary endpoint. Shares fell 2.4% on April 2 following the announcement.
Under the HanAll Agreement, Immunovant is developing batoclimab in partnership with HanAll Biopharma. Per the deal, Immunovant holds exclusive rights to develop and commercialize batoclimab in key global markets, while HanAll remains the originator of the molecule and retains rights outside the licensed territory.
Year to date, Immunovant shares have lost 3.6% against the industry’s 5.7% growth.
Image Source: Zacks Investment Research
Key Highlights of IMVT’s Phase III Batoclimab Studies for TEDBased on the pre-specified statistical analysis plan, neither study evaluating batoclimab for TED patients met the primary endpoint of a 2 millimeters or greater proptosis responder rate at week 24, after 12 weeks of high-dose followed by 12 weeks of low-dose batoclimab treatment.
Despite the setback, the therapy demonstrated a safety profile consistent with prior studies, with no new safety concerns identified.
Notably, patients experienced greater improvements in proptosis from baseline during the initial 12-week high-dose treatment phase compared to the subsequent 12-week low-dose period, underscoring the potential advantage of achieving deeper IgG suppression.
Among hyperthyroid patients in the TED studies, thyroid hormone normalization rates were consistent with those observed in the phase II study of batoclimab in Graves’ disease (GD), reinforcing the therapy’s biological activity in this population.
Immunovant intends to review future development plans for batoclimab with its partner HanAll Biopharma and provide an update at a later date.
The company remains focused on advancing IMVT-1402, its investigational FcRn blocker, across multiple autoimmune diseases, with GD identified as a key strategic priority. Top-line data from potentially registrational IMVT-1402 studies in GD are expected in 2027.
IMVT’s Zacks Rank & Stocks to ConsiderImmunovant currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals (ANIP - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 5.8% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 15.1% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.14 to $8.99 for 2026. Year to date, shares of ANIP have declined 6%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Arcus Biosciences (NYSE:RCUS – Get Free Report) and Immunovant (NASDAQ:IMVT – Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.
Institutional & Insider Ownership 92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation This table compares Arcus Biosciences and Immunovant”s top-line revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcus Biosciences $247.00 million 11.31 -$353.00 million ($3.30) -6.75 Immunovant N/A N/A -$413.84 million ($2.69) -9.11 Arcus Biosciences has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Profitability This table compares Arcus Biosciences and Immunovant’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Arcus Biosciences -142.91% -65.77% -32.51% Immunovant N/A -63.17% -58.01% Volatility and Risk Arcus Biosciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
Analyst Recommendations This is a breakdown of recent recommendations and price targets for Arcus Biosciences and Immunovant, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 1 3 7 1 2.67 Immunovant 1 4 6 0 2.45 Arcus Biosciences presently has a consensus price target of $30.80, suggesting a potential upside of 38.18%. Immunovant has a consensus price target of $32.00, suggesting a potential upside of 30.61%. Given Arcus Biosciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Immunovant.
Summary Arcus Biosciences beats Immunovant on 11 of the 14 factors compared between the two stocks.
About Arcus Biosciences (Get Free Report)
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
About Immunovant (Get Free Report)
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAir Canada (OTCMKTS:ACDVF) Given Consensus Rating of “Hold” by Analysts
NEXT HEADLINE »Head-To-Head Contrast: Lifetime Brands (LCUT) & Its Peers
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CTO Jay Stout sold 2,754 shares of Immunovant stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total transaction of $81,573.48. Following the completion of the sale, the chief technology officer directly owned 251,685 shares in the company, valued at $7,454,909.70. This represents a 1.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Immunovant Stock Performance Immunovant stock opened at $28.58 on Monday. The company’s fifty day moving average price is $25.99 and its 200 day moving average price is $24.75. Immunovant, Inc. has a 1 year low of $13.36 and a 1 year high of $30.09. The stock has a market capitalization of $5.82 billion, a P/E ratio of -10.62 and a beta of 0.67.
Immunovant (NASDAQ:IMVT – Get Free Report) last released its quarterly earnings results on Friday, February 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.11. During the same quarter last year, the firm posted ($0.76) earnings per share. Sell-side analysts predict that Immunovant, Inc. will post -2.67 EPS for the current year.
Wall Street Analysts Forecast Growth Several equities research analysts have issued reports on the stock. Truist Financial lifted their target price on shares of Immunovant from $16.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Sanford C. Bernstein assumed coverage on shares of Immunovant in a research note on Friday, March 20th. They set a “market perform” rating and a $28.00 target price on the stock. Wolfe Research raised shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research note on Tuesday, January 6th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Immunovant in a research note on Tuesday, February 10th. Finally, The Goldman Sachs Group lifted their target price on shares of Immunovant from $29.00 to $32.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $32.44.
Read Our Latest Report on Immunovant
Institutional Trading of Immunovant Several institutional investors and hedge funds have recently bought and sold shares of IMVT. RTW Investments LP purchased a new stake in Immunovant in the 4th quarter valued at about $80,781,000. Morgan Stanley raised its holdings in Immunovant by 147.4% in the 4th quarter. Morgan Stanley now owns 4,846,385 shares of the company’s stock valued at $123,195,000 after buying an additional 2,887,359 shares during the period. ADAR1 Capital Management LLC raised its holdings in Immunovant by 319.0% in the 3rd quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock valued at $36,137,000 after buying an additional 1,706,687 shares during the period. Logos Global Management LP raised its holdings in Immunovant by 400.0% in the 4th quarter. Logos Global Management LP now owns 1,375,000 shares of the company’s stock valued at $34,952,000 after buying an additional 1,100,000 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Immunovant by 14.0% in the 4th quarter. Vanguard Group Inc. now owns 7,779,314 shares of the company’s stock valued at $197,750,000 after buying an additional 952,504 shares during the period. 47.08% of the stock is currently owned by hedge funds and other institutional investors.
Immunovant Company Profile (Get Free Report)
Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.
The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.
Recommended Stories Five stocks we like better than Immunovant
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINESEA (NYSE:SE) Insider Sells $68,792.00 in Stock
NEXT HEADLINE »Ionis Pharmaceuticals (IONS) Projected to Post Earnings on Wednesday
DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026.
Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.
Matthew Klein, CEO of Roivant, said the company has had “a pretty wild 12 months,” citing progress across multiple programs and a series of expected milestones over the next year. The most prominent update was preliminary open-label data from a study of IMVT-1402 in difficult-to-treat rheumatoid arthritis, a program run by Immunovant NASDAQ: IMVT.
Get Immunovant alerts:
IMVT-1402 Shows Open-Label Activity in Difficult-to-Treat Rheumatoid Arthritis Klein said the preliminary open-label period data from the 1402 study in difficult-to-treat rheumatoid arthritis were “surprisingly good,” while cautioning that the results came from an open-label portion of the trial.
The study enrolled heavily refractory patients who had failed steroids, DMARDs and at least two advanced lines of therapy. Roivant said the trial also required ACPA positivity above a specified threshold. The study included 165 evaluable patients, with a baseline DAS28 CRP score of 6.1, which Klein described as reflecting “quite a sick patient population.”
In the 16-week open-label treatment period, patients received 600 milligrams of IMVT-1402. Roivant reported approximately 73% ACR20 responses, more than half of patients achieving ACR50 responses and more than one-third achieving ACR70 responses.
Klein said the depth of responses was particularly notable. “Once you get onto the deeper end of that with ACR 50s and ACR 70s, you just don’t see a lot of placebo response in that level of responder analysis,” he said.
The company also highlighted a subset of 107 patients who were both JAK inhibitor- and TNF-experienced. Klein said the response rates were “basically fully preserved” in that group, which he said supported the company’s thesis that targeting autoantibody-positive disease could offer an orthogonal mechanism for patients who have failed other anti-inflammatory therapies.
Roivant said IMVT-1402 was safe and well-tolerated in the study, with no new drug-related safety signals identified. In response to an analyst question, Klein said the company has seen “no impact on albumin or LDL” across hundreds of patients dosed with 1402, though he did not provide specific numerical data from the rheumatoid arthritis trial.
Randomized Withdrawal Data Still Pending The second period of the rheumatoid arthritis study is a 12-week randomized withdrawal phase in which ACR20 responders from weeks 14 and 16 are re-randomized to 600 milligrams, 300 milligrams or placebo. Klein said that portion is still ongoing, with more than half of patients still being dosed, and no data from that period were shared on the call.
Klein cautioned that the strong open-label responses could make the withdrawal portion harder to interpret. He said the primary endpoint asks whether patients taken off drug lose their ACR20 response within 12 weeks, but patients who achieved ACR50 or ACR70 responses may take longer to fall below the ACR20 threshold.
“There are plenty of scenarios where we don’t see a P value in period 2 and continue forward with the drug given the overall quality of this data,” Klein said. He added that Roivant expects to share more patient-level analysis and feedback from discussions with the FDA in the second half of the year.
Klein said prior commercial analysis suggested the target population could be at least 70,000 patients, while more recent analysis by Immunovant indicated the number could be 85,000 or higher.
Mosliciguat Readout Expected in PH-ILD Roivant also previewed mosliciguat, an inhaled sGC activator being developed for pulmonary hypertension associated with interstitial lung disease, or PH-ILD. Top-line data from the Phase IIb FOCUS study are expected in the second half of 2026.
Andrew Fromkin, CEO of Priovant, said mosliciguat is designed to activate sGC directly in the lungs and restore impaired sGC function. The company believes the drug could address both pulmonary vascular disease and lung parenchymal disease in PH-ILD.
Fromkin said prior Phase I studies conducted by Bayer included 170 participants, including healthy volunteers and pulmonary hypertension patients. In a Phase Ib study, a single dose of mosliciguat produced a mean PVR reduction of more than 30% and a mean peak PVR reduction of about 38%. Fromkin also said the drug was well-tolerated, with mild-to-moderate treatment-emergent adverse events and no significant cough observed.
The FOCUS study enrolled 135 patients, above the target of 120. The trial is randomized 2-to-1, drug to placebo, and uses change from baseline in pulmonary vascular resistance at week 16 as the primary endpoint. Secondary endpoints include six-minute walk distance and NT-proBNP.
Klein emphasized that the study is not powered to show a statistically significant benefit on six-minute walk distance. “What we’re really looking for is affirmation of dosing, affirmation of safety, affirmation of PVR in this patient population,” he said.
Roivant said PH-ILD affects up to approximately 200,000 patients in the U.S. and Europe and has fewer than five years of median survival in severe subgroups. Fromkin noted that only two FDA-approved treprostinil drugs are currently available.
Brepocitinib Commercial Preparations Continue Roivant also discussed brepocitinib, including commercial preparations for a potential launch in dermatomyositis by the end of September, assuming FDA action proceeds as expected. Klein said the company is engaged with payers, physicians and specialty pharmacies and has built a commercial team for the launch.
Klein said dermatomyositis patients have limited options, with many treated with steroids, IVIG and off-label therapies. He also noted that Phase III data for brepocitinib were published in the New England Journal of Medicine in March.
Roivant said additional brepocitinib-related catalysts include expected Phase III top-line data in non-infectious uveitis in the second half of the year, the planned start of a Phase III study in cutaneous sarcoidosis this year and an ongoing study in lichen planopilaris. Klein said lichen planopilaris has no FDA-approved therapies and may affect about 100,000 patients in the U.S.
Cash Position Strengthened by Moderna Settlement Roivant reported $4.3 billion in cash and cash equivalents as of March 31, before accounting for its Moderna settlement. Klein said the company expects to receive the first $950 million upfront payment from the $2.25 billion settlement in July.
The company said it has no debt and continued to repurchase shares during the quarter. Klein said research and development spending has grown over time as the scope of Roivant’s programs has expanded.
Other upcoming milestones include top-line data from a cutaneous lupus erythematosus proof-of-concept study in the second half of the year, ongoing Graves’ disease studies with data expected in 2027, and myasthenia gravis data also expected next year.
About Immunovant NASDAQ: IMVTImmunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.
The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Immunovant Right Now?Before you consider Immunovant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.
While Immunovant currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Immunovant shares are testing new highs. Why are IMVT shares at highs? Strong Trial Results Take Center StageThe company reported a quarterly loss of 73 cents per share, falling short of the 60 cents consensus estimate. Even so, traders pushed the stock higher as attention may have shifted to new results from the IMVT‑1402 program in difficult‑to‑treat rheumatoid arthritis (D2T RA). According to the filing, the therapy produced Week 16 ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8%, respectively.
The document states that 86.7% of participants had failed two prior mechanisms of treatment, and the average time since diagnosis was nearly 13 years.
High Response Rates In A Tough‑To‑Treat PopulationThe company highlighted that even among patients who had previously failed both a JAK inhibitor and an anti‑TNF therapy, response rates remained strong at Week 16, with ACR20 at 72%, ACR50 at 53.3% and ACR70 at 37.4%.
The initial 16‑week portion of the study was open‑label, but joint assessments were performed by independent evaluators who were blinded to treatment status. Immunovant believes this reduces the risk of bias. The company reported that IMVT‑1402 continued to show a favorable safety profile with no new safety signals identified.
Cash Position Supports Long‑Term PlansAs of March 31, 2026, Immunovant reported $902.1 million in cash and equivalents, which the company says is enough to fund development through the potential commercial launch of IMVT‑1402 in Graves' disease.
Research and development spending rose to $142.3 million for the quarter, driven by IMVT‑1402 trial activity and $39 million in costs tied to discontinuing batoclimab. Non‑GAAP R&D expenses for the full fiscal year reached $426.9 million, up from $333.9 million the prior year.
General and administrative expenses declined year-over-year, falling to $17.3 million. Net loss widened to $147.9 million from $106.4 million a year earlier.
IMVT Shares Are SoaringIMVT Price Action: Immunovant shares were up 35.87% at $35.72 at the time of publication on Wednesday. The stock is trading at a new 52-week high, according to Benzinga Pro.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
First Hawaiian (NASDAQ: FHB - Get Free Report) and California First Leasing (OTCMKTS:CFNB - Get Free Report) are both finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings. Profitability This table compares First Hawaiian and
HONOLULU, April 03, 2026 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its first quarter 2026 financial results on Friday, April 24, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company's results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time).
SG Americas Securities LLC increased its position in First Hawaiian, Inc. (NASDAQ: FHB) by 409.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,506 shares of the bank's stock after purchasing an additional 71,927 shares during the quarter.
Bayforest Capital Ltd lifted its holdings in First Hawaiian, Inc. (NASDAQ: FHB) by 725.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,229 shares of the bank's stock after buying an additional 18,658 shares during the
HONOLULU, April 24, 2026 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (NASDAQ:FHB), (“First Hawaiian” or the “Company”) today reported financial results for its quarter ended March 31, 2026.
First Hawaiian (FHB - Free Report) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.13%. A quarter ago, it was expected that this bank holding company would post earnings of $0.55 per share when it actually produced earnings of $0.56, delivering a surprise of +1.82%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
First Hawaiian, which belongs to the Zacks Banks - West industry, posted revenues of $220.35 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 0.4%. This compares to year-ago revenues of $211 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
First Hawaiian shares have added about 6.6% since the beginning of the year versus the S&P 500's gain of 3.8%.
What's Next for First Hawaiian?While First Hawaiian has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for First Hawaiian was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.55 on $223.19 million in revenues for the coming quarter and $2.23 on $901.59 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - West is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Avidbank Holdings Inc. (AVBH - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on April 27.
This company is expected to post quarterly earnings of $0.80 per share in its upcoming report, which represents a year-over-year change of +12.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Avidbank Holdings Inc.'s revenues are expected to be $28.2 million, up 37.4% from the year-ago quarter.
For the quarter ended March 2026, First Hawaiian (FHB - Free Report) reported revenue of $220.35 million, up 4.4% over the same period last year. EPS came in at $0.55, compared to $0.47 in the year-ago quarter.
The reported revenue represents a surprise of -0.4% over the Zacks Consensus Estimate of $221.24 million. With the consensus EPS estimate being $0.53, the EPS surprise was +3.13%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how First Hawaiian performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net charge-offs: 0.1% versus 0.2% estimated by four analysts on average.Total Non-Performing Assets: $39.68 million versus the four-analyst average estimate of $43.53 million.Net interest margin: 3.2% compared to the 3.2% average estimate based on four analysts.Efficiency Ratio: 57.8% compared to the 58.4% average estimate based on four analysts.Average Balance - Total Earning Assets: $21.33 billion versus the four-analyst average estimate of $21.2 billion.Total Non-Accrual Loans and Leases: $39.68 million compared to the $42.18 million average estimate based on three analysts.Total Noninterest Income: $52.82 million compared to the $54.7 million average estimate based on four analysts.Net Interest Income (FTE): $168.5 million compared to the $166.81 million average estimate based on four analysts.Net Interest Income: $167.53 million versus $166.26 million estimated by three analysts on average.Service charges on deposit accounts: $8.16 million versus the three-analyst average estimate of $8.11 million.Bank-owned life insurance: $4.09 million compared to the $5.25 million average estimate based on two analysts.Other service charges and fees: $13.78 million versus $13.59 million estimated by two analysts on average.View all Key Company Metrics for First Hawaiian here>>>
Shares of First Hawaiian have returned +9.6% over the past month versus the Zacks S&P 500 composite's +8.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
After reaching an important support level, First Hawaiian, Inc. (FHB) could be a good stock pick from a technical perspective. FHB recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Given its asset-sensitive balance sheet, First Hawaiian stands to benefit from the reduced likelihood of interest rate cuts. FHB's capital levels are rebounding toward pre-2022 levels, enabling it to resume meaningful share repurchases and supporting its shareholder yield. At under 12x earnings, FHB offers a high single-digit shareholder yield and trades at a discount to the industry. With a lower-risk loan book, this looks attractive.
TORONTO, ON / ACCESS Newswire / May 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on May 22nd, 2026, to shareholders of record at the close of business on May 14th, 2026.
TORONTO, ON / ACCESS Newswire / May 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the quarter ended March 31, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise.
HIGHLIGHTS
For the quarter ended March 31, 2026 consolidated energy production decreased by 5% compared to the same quarter in 2025, with total production of 205,317 MWh versus 216,344 MWh for the quarter ended March 31, 2025. The decrease was attributable to the scheduled major maintenance in Nicaragua, with no major maintenance in the comparative period, as well as higher curtailment in the Dominican Republic. This was partially offset by improved production in Peru and a full quarter of operating results from Puerto Rico, compared to only one month of contribution following its acquisition in 2025.
The Company generated $19.8 million in revenue for the quarter ended March 31, 2026, compared to $20.3 million in 2025. The decrease in revenue is mainly attributable to lower energy production during the quarter.
Adjusted EBITDA was $13.5 million for the quarter ended March 31, 2026, compared to Adjusted EBITDA of $15.0 million in the same period in 2025.
Net loss attributable to shareholders, was $0.6 million or $(0.03) per share - basic for the quarter ended March 31, 2026, compared to net loss of $10.4 million or $(0.49) per share - basic in 2025.
For the quarter ended March 31, 2026, the Company generated $8.5 million in net cash flow from operating activities, ending with a cash position of $97.5 million, including restricted cash of $5.6 million.
On February 19, 2026, the Governing Board of the Puerto Rico Electric Power Authority ("PREPA") approved the Battery Energy Storage System Standard Offer ("SO1") Agreement, and Polaris received formal written notice of such approval on February 27, 2026. The execution of the SO1 Agreement remains subject to approval from the Financial Oversight and Management Board ("FOMB"). Upon receipt of this last approval, the Battery Energy Storage System ("BESS") project, with a total capacity of 71.4 MW, is expected to advance to construction, which is currently estimated to take approximately 12 months, after which Polaris would be entitled to receive monthly fixed and performance-based payments for providing energy storage, capacity and grid support services over a 20-year term.
The Company remains focused on maintaining a quarterly dividend. In respect to the three months ended March 31, 2026, the Company has declared and will pay a quarterly dividend of $0.15 per outstanding common share on May 22, 2026, to shareholders of record as of May 14, 2026.
OPERATING AND FINANCIAL OVERVIEW
Three Months Ended
(Expressed in thousands of USD, unless otherwise indicated)
March 31, 2026
March 31, 2025
Energy production
Consolidated Power MWh
205,317
216,344
Financials
Total revenue
$
19,768
$
20,287
Net earnings (loss) attributable to owners
$
(631
)
$
(10,441
)
Adjusted EBITDA
$
13,464
$
15,031
Net cashflow from operating activities
$
8,531
$
11,767
Per share
Net earnings (loss) attributable to owners - basic and diluted
$
(0.03
)
$
(0.49
)
Dividends declared per common share
$
0.15
$
0.15
Adjusted EBITDA per share- basic
$
0.64
$
0.71
Balance Sheet
As at March 31,
2026
As at
December 31, 2025
Total cash and cash equivalents (Restricted and Unrestricted)
$
97,539
$
93,200
Total current assets
$
106,800
$
103,258
Total assets
$
533,256
$
535,569
Current and Long-term debt
$
217,637
$
217,344
Total liabilities
$
294,068
$
292,692
During the three months ended March 31, 2026, quarterly consolidated energy decrease was primarily attributable to a scheduled major maintenance outage in Nicaragua in February 2026, whereas no major maintenance activities were undertaken in the prior-year period together with a higher curtailment in the Dominican Republic. These factors were partially offset by improved production in Peru and the inclusion of a full quarter of operating results from Puerto Rico, compared to only one month of contribution following its acquisition in 2025.
In Peru, production increased compared to the same period in 2025, reflecting improved hydrological conditions and strong resource availability.
In the Dominican Republic, production declined due to elevated curtailment levels during the quarter. Curtailment reached approximately 42% (6,775 MWh) in Q1 2026, compared to significantly lower levels in the prior year, materially impacting realized generation despite adequate solar resource availability. While curtailment has moderated to approximately 30% quarter-to-date in Q2 2026, the timing of a return to normalized levels is not yet clear. The Government is pursuing the implementation of grid-scale storage to alleviate a significant part of the problem which we anticipate could be implemented in timeframe of approximately 18-24 months.
In Puerto Rico, production at the plant for the quarter was comparable to 2025. However, the prior year period only included generation from the March acquisition date, whereas the current year reflects a full quarter of operations.
In Ecuador and Panama, production was consistent with the comparative period in 2025, reflecting stable resource availability.
"During the first quarter of 2026, Polaris delivered resilient operating performance despite temporary headwinds including scheduled maintenance in Nicaragua and elevated curtailment in the Dominican Republic, with impacts partially offset by strong results in Peru and contributions from our Puerto Rico wind asset, underscoring the strength of our underlying business and solid liquidity position. We continued to advance key strategic initiatives and we look forward to sharing positive developments from our pipeline in the coming quarter as we remain focused on disciplined growth and long-term value creation," said Marc Murnaghan, Chief Executive Officer of Polaris Renewable Energy.
About Polaris Renewable Energy Inc.
Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition.
The Company's operations include a geothermal plant (82 MW), four run-of river hydroelectric plants (39 MW), three solar (photovoltaic) projects (35 MW) and an onshore wind farm (26 MW).
For more information, contact :
Investor Relations
Polaris Renewable Energy Inc.
Phone: +1 647-245-7199
Email: [email protected]
Cautionary Statements
This news release contains "forward-looking information" within the meaning of applicable Canadian securities laws, which may include, but is not limited to, financial and other projections as well as statements with respect to future events or future performance, management's expectations regarding the Company's growth, results of operations, business prospects and opportunities. n addition, statements relating to estimates of recoverable energy "resources" or energy generation capacities are forward-looking information, as they involve implied assessment, based on certain estimates and assumptions, that electricity can be profitably generated from the described resources in the future. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "estimates", "goals", "intends", "targets", "aims", "likely", "typically", "potential", "probable", "projects", "continue", "strategy", "proposed", or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved.
Forward-looking information in this MD&A includes, but is not limited to: the expected production capacity of the Binary Unit at San Jacinto; additional changes to the wells and steamfield to increase production; the ability to successfully capitalize on expansion opportunities in Puerto Rico and the Dominican Republic and to increase the load factor on Canoa Solar Park in Dominican Republic; future dividends; expected annual energy production; sufficiency of cash flows from operations; the ability to satisfy capital requirements and the replacement of debt; the result of changes to the re-injection system over the long-term; and the verification process and timing regarding the sale of carbon emission credits.
A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. Such factors include, among others: failure to discover and establish economically recoverable and sustainable resources through exploration and development programs; imprecise estimation of probability simulations prepared to predict prospective resources or energy generation capacities; variations in project parameters and production rates; defects and adverse claims in the title to the Company's properties; failure to obtain or maintain necessary licenses, permits and approvals from government authorities; the impact of changes in foreign currency exchange and interest rates; changes in government regulations and policies, including laws governing development, production, taxes and global tariffs, labour standards and occupational health, safety, toxic substances, resource exploitation and other matters; availability of government initiatives to support renewable energy generation; increase in industry competition; fluctuations in the market price of energy; impact of significant capital cost increases; the ability to file adjustments in respect of applicable power purchase agreements; unexpected or challenging geological conditions; changes to regulatory requirements, both regionally and internationally, governing development, geothermal or hydroelectric resources, production, exports, taxes and global tariffs, labour standards, occupational health, waste disposal, toxic substances, land use, environmental protection, project safety and other matters; economic, social and political risks arising from potential inability of end-users to support the Company's properties; insufficient insurance coverage; inability to obtain equity or debt financing; fluctuations in the market price of the common shares; inability to retain key personnel; the risk of volatility in global financial conditions, as well as a significant decline in general economic conditions; uncertainty of political stability in countries and territories in which the Company operates; uncertainty of the ability of Nicaragua, Peru, Panama, Dominican Republic, Ecuador and Puerto Rico to sell power to neighbouring countries; economic insecurity in Nicaragua, Peru, Panama, Dominican Republic, Ecuador and Puerto Rico. These factors are not intended to represent a complete list of the risk factors that could affect us.
Such forward-looking information is based on a number of material factors and assumptions, including: the Company's historical financial and operating performance; that contracted parties provide goods and/or services on the agreed timeframes; the success and timely completion of planned exploration and expansion programs, including the Company's ability to comply with local, state and federal regulations dealing with operational standards and environmental protection measures; the Company's ability to negotiate and obtain PPAs on favourable terms; the Company's ability to obtain necessary regulatory approvals, permits and licenses in a timely manner; the availability of materials, components or supplies; the Company's ability to solicit competitive bids for drilling operations and obtain access to critical resources; the growth rate in net electricity consumption; continuing support and demand for renewables; continuing availability of government initiatives to support the development of renewable energy generation; the accuracy of volumetric reserve estimation methodology and probabilistic analysis used to estimate the quantity of potentially recoverable energy; environmental, administrative or regulatory barriers to the exploration and development of geothermal or hydroelectric resources of the Company's properties; geological, geophysical, geochemical and other conditions at the Company's properties; the reliability of technical data, including hydrological, extrapolated temperature
gradient, geophysical and geochemical surveys and geothermometer calculations; the accuracy of capital expenditure estimates; availability of all necessary capital to fund exploration, development and expansion programs; the Company's competitive position; the ability to continue as a going concern and general economic conditions.
Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking information contained herein is provided as at the date of this MD&A and the Company disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, except as required by applicable laws. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information due to the inherent uncertainty therein.
Additional information about the Company, including the Company's AIF for the year ended December 31, 2025 is available on SEDAR+ at www.sedarplus.ca and on the Company's website at www.polarisREI.com.
Non-GAAP Performance Measures
Certain measures in this press release do not have any standardized meaning as prescribed by IFRS and, therefore, are not considered GAAP measures. Where non-GAAP measures or terms are used, definitions are provided. In this document and in the Company's consolidated financial statements, unless otherwise noted, all financial data is prepared in accordance with IFRS.
This news release includes references to the Company's adjusted earnings before interest, taxes, depreciation and amortization ("adjusted EBITDA") and adjusted EBITDA per share, which are non-GAAP measures. These measures should not be considered in isolation or as an alternative to net earnings (loss) attributable to the owners of the Company or other measures of financial performance calculated in accordance with IFRS. Rather, these measures are provided to complement IFRS measures in the analysis of Polaris Renewable Energy's results since the Company believes that the presentation of these measures will enhance an investor's understanding of Polaris Renewable Energy's operating performance. Management's determination of the components of non-GAAP performance measures are evaluated on a periodic basis in accordance with its policy and are influenced by new transactions and circumstances, a review of stakeholder uses and new applicable regulations. When applicable, changes to the measures are noted and retrospectively applied.
Descriptions and reconciliations of the above noted non-GAAP performance measures are included in Section 13: Non-GAAP Performance Measures in the Company's MD&A for the quarter ended March 31, 2026 and on the Company's website www.polarisREI.com/Non-GAAP.
TORONTO, ON / ACCESS Newswire / May 12, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that, on May 8, 2026, the Financial Oversight and Management Board of Puerto Rico ("FOMB") approved the Battery Energy Storage System ("BESS") Standard Offer Agreement ("SO1 Agreement"). The approval of the FOMB completes the three-steps approval process for the SO1 Agreement, following prior regulatory approvals obtained from the Puerto Rico Energy Bureau ("PREB") and the Governing Board of the Puerto Rico Electric Power Authority ("PREPA").
LONDON & MONTREAL--(BUSINESS WIRE)--Behavox, an AI company providing unified controls frameworks for financial institutions, today announced that Polaris, its trade surveillance platform, now covers prediction markets as a new asset class — bringing Polaris's out-of-the-box risk coverage to 10 asset classes. Prediction markets coverage is available in beta to existing Polaris customers immediately, with general availability scheduled for summer 2026. "We are getting consistent feedback from cus.
– ETX101 demonstrated robust and durable seizure reductions through 52 weeks after a single dose –
– Clinically-meaningful improvements in multiple adaptive behavior domains were observed, demonstrating measurable gains in daily functioning –
– ETX101 demonstrated the potential to rescue developmental stagnation in the youngest treated children, with 52-week cognitive trajectories within the neurotypical range –
– Favorable safety profile across all four dose levels, with no treatment‑related serious adverse events –
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics, Inc. (“Encoded”), a clinical‑stage biotechnology company developing precision genetic medicines for severe neurological disorders, today will present an expanded dataset from the ongoing POLARIS Phase 1/2 trials of ETX101, its investigational AAV9‑based gene regulation therapy designed as a one‑time, disease‑modifying treatment for SCN1A+ Dravet syndrome. The update includes additional patients, early data from the top dose level (DL4), and longer‑term outcomes that further define the emerging clinical profile of ETX101 in children aged 6 months to 7 years. These results will be featured in an oral presentation during the Presidential Symposium (Wednesday, May 13, 2:28–2:39 p.m. ET) at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
Watching these young children not only achieve durable seizure reduction but also show early evidence of neurodevelopmental rescue is truly remarkable.
Share Treatment with a single dose of ETX101 resulted in a robust and dose-dependent antiseizure effect, with durability through 52 weeks of observation. Clinically meaningful improvements in adaptive behavior were reported across the full age range tested. Notably, children treated before age 2 rapidly diverged from the developmental stagnation expected from natural history, with cognitive trajectories generally consistent with neurotypical development.
“Parents of children with Dravet syndrome live with the fear of every seizure and the heartbreak of watching development stall,” said Mary Anne Meskis, CEO of the Dravet Syndrome Foundation. “To see the early and robust seizure reductions paired with meaningful developmental gains is profoundly encouraging. Families have been waiting for therapies that don’t just manage symptoms but give their children a chance to keep learning and growing.”
ASGCT Oral Presentation Highlights
All analyses reflect data through the April 10, 2026, data cutoff.
Seizure Reduction:
From Week 5 through Week 52, durable, dose-dependent antiseizure effects were observed with approximately a 76% median monthly countable seizure frequency (MCSF) reduction at DL3 (n=3) — during a developmental window typically associated with increasing seizure burden despite treatment with standard-of-care antiseizure medicines. Early data from DL4 demonstrated continued dose-dependent antiseizure activity, with the strongest response observed in patients who did not receive sirolimus (n=4), consistent with molecular and animal data showing that sirolimus dampens the therapeutic signal by reducing protein expression. No differences in safety outcomes were observed between patients that received sirolimus and those who did not. Neurodevelopmental Improvements:
Patients who reached 52 weeks of observation (n=9) demonstrated improvements in multiple domains of adaptive behavior based on the caregiver interview–based Vineland Adaptive Behavior Scales (VABS‑3). The most notable gains were observed in receptive and expressive communication and motor function, with meaningful progress also observed in self‑care and social interaction. In patients treated before age 2, progressive gains in cognition were evident as early as Week 16 (n=11) and continued through Week 52 (n=4), as measured by the Bayley Scales of Infant and Toddler Development (Bayley‑4). These data show that these young patients rapidly diverged from the stagnation seen in the ENVISION natural history study, with trajectories generally consistent with neurotypical development over the 52-week observation period. “Watching these young children not only achieve durable seizure reduction but also show early evidence of neurodevelopmental rescue is truly remarkable,” said Sal Rico, M.D., Ph.D., Chief Medical Officer of Encoded. “These data reinforce our belief that ETX101 has the potential to change the course of the disease and future outlook for the Dravet community.”
To date, ETX101 has shown a favorable safety profile and has been well-tolerated across all four dose levels, with no treatment- or procedure-related serious adverse events. The most common treatment-related adverse events were transaminase elevations (a known AAV class effect), which were clinically asymptomatic and resolved in all participants.
About the POLARIS Clinical Development Program
The POLARIS program is a comprehensive clinical investigation of ETX101 in children and adolescents with SCN1A+ Dravet syndrome, comprising multiple Phase 1-3 clinical trials. The first phase of POLARIS includes three ongoing open-label, Phase 1/2 dose-escalation, multicenter trials (ENDEAVOR Part 1 (US), EXPEDITION (UK), and WAYFINDER (Australia)) in infants and young children aged 6 months to 7 years. ENDEAVOR Part 1B, an expansion study in the US, is actively enrolling children and adolescents aged 4 to 18 years. These studies are evaluating the safety and preliminary efficacy of ETX101 in children and adolescents with Dravet syndrome due to variants in the SCN1A gene. The pivotal ENDEAVOR Part 2 study is also ongoing, evaluating seizure and neurodevelopmental outcomes in young children aged 6 months to 4 years.
About ETX101
ETX101 is an investigational AAV9-based gene regulation therapy designed to increase the expression of the SCN1A gene to restore sodium channel function in inhibitory interneurons. By targeting the root mechanism, ETX101 has the potential to treat the full spectrum of Dravet syndrome symptoms, including seizures, communication and cognitive impairment, behavioral issues, and motor dysfunction. The therapy is administered via a single intracerebroventricular (ICV) injection and is designed for long-term benefit. ETX101 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA. It also was selected for the FDA’s CMC Development and Readiness Pilot (CDRP) Program and received Orphan designation from the European Medicines Agency (EMA).
About Encoded Therapeutics
Encoded Therapeutics is a clinical-stage biotechnology company developing one-time precision genetic medicines for severe monogenic and common neurological disorders. The company’s vector engineering platform enables highly targeted and cell-type-selective control of gene expression in the brain and peripheral nervous system, allowing potent and precise modulation of disease-relevant genes to address underlying disease biology. Encoded’s end‑to‑end innovation engine—spanning discovery, development, and in‑house GMP manufacturing—creates a streamlined path to advance a diversified pipeline of one‑time treatments across a broad range of neurological conditions. Encoded is driven by a mission to meaningfully improve the lives of patients and families affected by devastating neurological disorders. For more information, please visit www.encoded.com.
DALLAS, May 20, 2026 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking, and blockchain workloads, today announced it has entered into a long-term lease agreement with the same U.S. based high investment-grade hyperscaler that previously signed at Delta Forge 1. The agreement is for the Company’s fourth AI Factory campus, Polaris Forge 3, located in a northern state and designed to deliver 300 MW of critical IT load, supported by approximately 430 MW of grid-connected utility power.
Key Transaction Highlights:
15-year take-or-pay leases with the same U.S. based high investment-grade hyperscaler previously signed at Delta Forge 1, valued at approximately $7.5 billion in base-term contracted revenue, $18.2 billion if all options are exercised.300 MW of critical IT load, purpose-built for large-scale AI training and inference workloads.Brings Applied Digital’s total contracted lease revenue to $31 billion across four AI Factory campuses, $73 billion if all renewal options at each campus are exercised in accordance with their terms.Approximately 65% of contracted revenue backed by U.S. based investment-grade hyperscalers.Total contracted capacity across four AI Factory campuses now reaches 1,200 MW of critical IT load (net) and approximately 1,670 MW of utility power (gross).
The leases represent approximately $7.5 billion in total contracted value over an estimated 15-year take-or-pay term and are designed to deliver 300 megawatts (MW) of critical IT load to support the hyperscaler's artificial intelligence (AI) and high-performance compute (HPC) infrastructure needs at scale. Including all renewal options, the agreements carry a total potential value of up to approximately $18.2 billion, which we believe further strengthens the long-term revenue visibility of Applied Digital's portfolio.
With these agreements, we believe Applied Digital further solidifies its position as the partner of choice for the world’s most demanding hyperscalers. Polaris Forge 3 represents the Company’s second long-term lease with this U.S. based high investment-grade hyperscaler, further expanding the strategic relationship established at Delta Forge 1 in April 2026.
“Polaris Forge 3 is a direct extension of what we’ve proven works: a disciplined, repeatable AI Factory model that delivers large-scale capacity to the world’s most demanding compute customers,” said Wes Cummins, Chairman and Chief Executive Officer of Applied Digital. “This second 300 MW lease with the same U.S. based high investment-grade hyperscaler we partnered with at Delta Forge 1 reflects the confidence we’ve built through disciplined execution and our ability to consistently advance large-scale AI infrastructure projects. We’ve earned a seat at the table with blue-chip customers, and we intend to keep that position through flawless execution and long-term operational reliability.”
“Momentum continues to build for our Company,” Cummins continued, “While executing leases representing 1.2 GW in the past eleven months has been a monumental achievement, we are actively marketing more than 1.7 GW of grid-connected utility power across sites recently added to our portfolio, as well as existing sites.”
Polaris Forge 3 spans more than 600 acres and is engineered from the ground up for high-density AI workloads. The campus integrates Applied Digital's proprietary waterless cooling technology, high-density power delivery, and advanced liquid-cooling architecture, all purpose-built to support the compute densities demanded by next-generation AI infrastructure.
Built on Applied Digital's proven AI Factory model (the same framework powering Polaris Forge 1, Polaris Forge 2, and Delta Forge 1), Polaris Forge 3 extends the Company’s repeatable campus strategy into another large-scale AI deployment. Initial operations at Polaris Forge 3 are anticipated to commence in August 2027.
About Applied Digital
Applied Digital (Nasdaq: APLD) named Best Data Center in the Americas 2025 by Datacloud — designs, builds, and operates high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking, and blockchain workloads. Headquartered in Dallas, TX, and founded in 2021, the company combines hyperscale expertise, proprietary waterless cooling, and rapid deployment capabilities to deliver secure, scalable compute at industry-leading speed and efficiency, while creating economic opportunities in underserved communities through its award-winning Polaris Forge AI Factory model.
Learn more at applieddigital.com or follow @APLDdigital on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position, business strategy and objectives, and future financing plans. These statements use words, and variations of words, such as “will,” “continue,” “build,” “future,” “increase,” “drive,” “believe,” “look,” “ahead,” “confident,” “proven,” “deliver,” “outlook,” “expect,” “project” and “predict.” Other examples of forward-looking statements may include, but are not limited to, (i) statements that reflect perspectives and expectations regarding lease agreements and any current or prospective data center campus development; (ii) statements about the high-performance computing (HPC) industry; (iii) statements of company plans and objectives, including the company’s evolving business model, or estimates or predictions of actions by suppliers; (iv) statements of future economic performance; (v) statements of assumptions underlying other statements and statements about the company or its business; and (vi) the company’s plans to obtain future project financing. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the company’s expectations and projections. These risks, uncertainties, and other factors include, among others: whether or not our customers exercise the renewal options under their leases with us (if not, we will not recognize further revenue from such customer under its respective lease); our ability to complete construction of our data center campuses as planned; the lead time of customer acquisition and leasing decisions and related internal approval processes; changes to artificial intelligence and HPC infrastructure needs and their impact on future plans; costs related to the HPC operations and strategy; our ability to timely deliver any services required in connection with completion of installation under lease agreements; our ability to raise additional capital to fund the ongoing datacenter construction and operations; our ability to obtain financing of datacenter leases and more broadly for our development and general corporate activities; our dependence on principal customers, including our ability to execute and perform our obligations under our leases with key customers; our ability to timely and successfully build new hosting facilities with the appropriate contractual margins and efficiencies; power or other supply disruptions and equipment failures; the inability to comply with regulations, developments and changes in regulations; cash flow and access to capital; availability of financing to continue to grow our business; decline in demand for our products and services; maintenance of third party relationships; and conditions in the debt and equity capital markets. A further list and description of these risks, uncertainties, and other factors can be found in the company’s most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, including in the sections captioned “Forward-Looking Statements” and “Risk Factors,” and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, on the company’s website (www.applieddigital.com) under “Investors,” or on request from the company. Information in this press release is as of the dates and time periods indicated herein, and the company does not undertake to update any of the information contained in these materials, except as required by law.
Annual report highlights progress across product innovation, environmental stewardship, community impact and employee development
, /PRNewswire/ -- Polaris Inc. (NYSE: PII) today released its 2025 Geared For Good Report. The annual report highlights Polaris' ongoing efforts to support its people, riders, communities and the outdoors while advancing toward its 2035 environmental goals.
Polaris Inc. released its 2025 Geared For Good Report highlighting the company's ongoing efforts to support its people, riders, communities and the outdoors while advancing toward its 2035 environmental goals.
At Polaris, rider safety is our priority, and safety and quality are at the core of everything we do, from how we design and source materials, to our manufacturing processes and shipment approach.
Polaris works to reduce our environmental impact and create efficiencies across our operations — from suppliers, manufacturing and distribution to our office facilities.
At Polaris, we seek to have a positive impact on the outdoor places where people use our products and are committed to protecting where we ride.
Polaris is committed to showing up for our riders, dealers, employees and the communities where we do business.
"Doing business the right way and being thoughtful stewards of our industry, our people and the outdoors is core to who we are at Polaris," said Holly Spaeth, Vice President, Brand & Powersports Marketing and Corporate Responsibility Committee Chair at Polaris. "This year's report reflects our commitment to being Geared For Good, highlighting how we're welcoming more people into powersports, investing in our communities, and making progress toward our long‑term environmental goals."
The report is organized around Polaris' four Geared For Good pillars: THINK PRODUCT, THINK PRODUCTION, THINK PLACES, and THINK PEOPLE. Highlights include:
THINK PRODUCT:
Expanded access to powersports by launching the RANGER 500, an approachable utility side‑by‑side starting at $9,999. Removed 100% of detectable PFAS in Klim's spring and fall lines. Earned industry recognition for best‑in‑class innovation, including honors for MRZR, Godfrey Sanpan, and Hurricane SunDeck 3200. THINK PRODUCTION:
Installed an 8,000 square meter solar array in Goupil, generating more than twice the facility's annual energy needs. Cut dunnage waste by 900 tons through the creation of reusable engine crates. Conserved more than 4 million gallons of water year over year. THINK PLACES:
Supported trail and conservation projects across five states through the fully funded Polaris Fund for Outdoor Recreation in partnership with the National Forest Foundation. Donated $255,000 via TRAILS GRANTS, supporting trail stewardship and rider education. Raised $10,000 for Advocates for Multi‑Use Public Lands and local riding clubs, expanding snowmobile access. THINK PEOPLE:
Strengthened communities with more than $5.6 million in corporate donations, grants and employee giving. Invested $80,000 in S.T.E.P. scholarships, providing over 1,000 students, from 45 schools, free access to Polaris technician training. Advanced leadership and skill development for more than 2,000 employees through the launch of Development Day. The report also highlights continued momentum toward Polaris' 2035 environmental goals, teams following ISO standards to evaluate vehicle recyclability, reducing GHG emissions by 10,000 metric tons of CO2e since 2023, overall 80% waste diversion, and 98% of miles driven with SmartWay.
To explore the full 2025 Geared For Good Report, visit Polaris.com/corporate-responsibility.
ABOUT POLARIS
As the global leader in powersports, Polaris Inc. (NYSE: PII) has been defining and redefining outdoor adventure since 1954. Polaris delivers industry-shaping off-road vehicles, snowmobiles, boats, military, quadricycles, and commercial transportation vehicles, along with an expansive portfolio of parts, garments, and accessories. Its lineup includes some of the most iconic brands in powersports including the RANGER, RZR, Polaris XPEDITION, Bennington pontoons, Slingshot, and more. Headquartered in Minnesota and serving customers in nearly 100 countries, Polaris continues to set the standard for performance, quality, and unmatched service. Explore more at www.polaris.com.
Applied Digital (APLD) rallied on May 21 after Needham said the firm's 15-year lease agreement for 300 MW of critical capacity at its advanced Polaris Forge 3 data center campus in North Dakota will drive its share price higher. In a research note this morning, analyst John Todaro told clients that the multi-billion-dollar hyper-scaler commitment offers exceptional visibility and predictability into future revenue.
On May 21, 2026, Polaris Inc PII shares rose 5.1% to a current price of $66.27. The stock has traded within a 52-week range of $36.73 to $75.25, reflecting significant volatility. The recent increase in share price underscores a positive momentum in the market.
GF Value™ verdict: Current price at $66.27 is 4.0% below the GF Value™ of $69.06, indicating it is undervalued.GF Score™ of 75/100 suggests that Polaris Inc is above average in terms of overall stock quality.Notable signal: No insider transactions have been reported in the last 3 months. Is PII Overvalued or Undervalued? Polaris Inc’s current trading price of $66.27 is 4.0% below the GF Value™ of $69.06, indicating that the stock is undervalued at this time. This margin of safety provides a potential opportunity for investors who are looking for a stock that is trading below its intrinsic value. The GF Valuation label categorizes the stock as fairly valued, which suggests that while there is some upside, caution is advised as market conditions can change. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the stock appears to be undervalued, potential investors should consider the overall market conditions and the company's financial health as indicated by its GF Score™ and other proprietary metrics. The current market sentiment can impact the stock's price, thus adding a layer of risk to the valuation assessment.
How Does PII's Valuation Compare to Its History? Metric Current Historical P/E (TTM) Not Available 14.3x Forward P/E 36.5x Not Applicable Since the P/E (TTM) is not available, we cannot directly compare it to its historical valuation. However, the forward P/E of 36.5x suggests that the stock may be trading at a higher valuation compared to its historical median P/E of 14.3x. This analysis does not completely align with the GF Value™ verdict, which indicates the stock is undervalued. Investors should be cautious and consider both the future earnings potential and the current market conditions before making decisions.
What Does PII's GF Score™ Tell Us? Metric Rating GF Score™ 75 Financial Strength 5/10 Profitability 7/10 Growth 3/10 Valuation 10/10 Momentum 8/10 The GF Score™ of 75/100 indicates that Polaris Inc has an above-average overall stock quality. The strongest area is its Valuation score of 10/10, suggesting that the stock is favorably priced relative to its intrinsic value. However, the Growth rank of 3/10 highlights a potential concern regarding the company's ability to expand its revenue or earnings in the future. The Financial Strength score of 5/10 indicates a balanced position, while a Profitability rank of 7/10 suggests solid profitability metrics. Overall, while the valuation appears attractive, investors should monitor growth potential as a critical factor.
What Are Insiders Doing with PII Stock? There have been no insider transactions reported in the last 3 months for Polaris Inc. This lack of insider activity suggests a neutral stance from those with the most intimate knowledge of the company. In general, insider buying can be a positive signal, while lack of activity can indicate that insiders are not making significant moves based on their expectations of the company's future performance.
What This Means for Investors Based on the GF Value™ assessment, Polaris Inc PII is currently undervalued. However, potential investors should take into account the stock's historical performance and growth potential as indicated by its metrics. The combination of a positive GF Score™ and an undervalued stock price presents an interesting opportunity, but market dynamics and company fundamentals should be closely monitored.
For the complete analysis, visit the Polaris Inc PII stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is PII's GF Score™?
PII's GF Score™ is 75/100, indicating that it has above-average stock quality based on key financial metrics.
Is PII overvalued or undervalued?
PII is currently undervalued with a GF Value™ of $69.06 compared to its current price of $66.27.
What is PII's P/E ratio?
The TTM P/E ratio is not available, while the forward P/E is 36.5x, suggesting a higher valuation compared to its historical median P/E of 14.3x.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Defines a new enterprise architecture for governing APIs, data and AI systems across hybrid and multi-cloud environments
, /PRNewswire/ -- Persistent Systems (BSE: 533179) (NSE: PERSISTENT), a global Digital Engineering and Enterprise Modernization leader and Kong, a leading developer of API and AI connectivity, today announced a strategic partnership to help enterprises implement the control layer required to scale AI securely and reliably. Persistent is uniquely positioned as Kong's global systems integration partner, combining its engineering-led approach with Kong's unified API and AI connectivity platform to simplify integration, strengthen governance and accelerate enterprise AI adoption.
As enterprises move from AI experimentation to production, the challenge is no longer access to models. It is how AI systems are connected, governed and operated at scale. APIs, data pipelines, models and agents are converging into a single operational fabric. Without a unified control layer, this fabric becomes fragmented, difficult to govern and increasingly complex to scale.
This partnership addresses that gap by enabling enterprises to implement Kong's governed, scalable connectivity layer across APIs, data and AI services. Together, Persistent and Kong will enable organizations to modernize legacy API environments, strengthen governance and reduce operational costs, while supporting high-performance workloads seamlessly across hybrid and multi-cloud environments.
The collaboration also enables enterprises to operationalize GenAI and agentic workflows, including Model Context Protocol-based architectures, with built-in security, observability and policy-driven control. This includes policy-driven safeguards such as Personally Identifiable Information (PII) protection, centralized access management and end-to-end observability, ensuring enterprise-grade security and compliance across API and AI interactions.
The partnership advances Persistent's AI-first, platform-driven approach by creating a more predictable path from AI ambition to enterprise-scale execution. By combining Kong's AI Gateway and unified API and AI connectivity platform with Persistent's GenAI Hub and engineering-led delivery, organizations can move beyond isolated use cases toward governed, production-grade AI systems with greater control, lower risk and faster realization of business value.
"Enterprise AI will not be defined by who has access to models. It will be defined by how effectively organizations can govern how intelligence flows across their systems. APIs are no longer just integration points. They are the control layer for enterprise AI. Our partnership with Kong brings together Persistent's engineering-led approach with a unified connectivity platform to help clients move from fragmented AI initiatives to scalable, production-grade systems. Together, we are enabling enterprises to build AI that is secure, controlled and ready to deliver real business outcomes."
Ken Kim, Senior Vice President and Head of Business Development, Kong:
"Enterprises are moving fast to put AI into production, and APIs are critical for connecting services, data, and model endpoints across complex environments. At Kong, we are building the AI Connectivity infrastructure so organizations can secure, manage, govern, and scale traffic across APIs and AI workloads on any model or any cloud. We are excited to have Persistent as a key global integration partner, bringing deep digital engineering expertise that complements our unified API and AI platform. Together, we can help customers modernize integration and deploy enterprise AI with consistent policy enforcement, secure access controls, and strong observability and audit trails."
About Kong Inc.
Kong Inc., a leading developer of API and AI connectivity technologies, is building the connectivity layer of AI. Trusted by the Fortune 500® and AI-native startups alike, Kong's unified API and AI platform enables organizations to secure, manage, accelerate, govern, and monetize the flow of intelligence across APIs and AI traffic — on any model, any cloud. For more information, visit www.konghq.com.
About Persistent
Persistent Systems (BSE: 533179) (NSE: PERSISTENT) is a global services and solutions company delivering AI-led, platform-driven Digital Engineering and Enterprise Modernization to businesses across industries. With over 27,500 employees located in 21 countries, the Company is committed to innovation and client success. Persistent offers a comprehensive suite of services, including software engineering, product development, data and analytics, CX transformation, cloud computing, and intelligent automation. The Company is part of the MSCI India Index and is included in key indices of the National Stock Exchange of India, including the Nifty Midcap 50, Nifty IT, and Nifty MidCap Liquid 15, as well as several on the BSE such as the S&P BSE 100 and S&P BSE SENSEX Next 50. Persistent is also a constituent of the Dow Jones Best-in-Class World Index. The Company has achieved carbon neutrality, reinforcing its commitment to sustainability and responsible business practices. Persistent has also been named one of America's Greatest Workplaces for Inclusion & Diversity 2025 by Newsweek and Plant A Insights Group. As a participant of the United Nations Global Compact, the Company is committed to aligning strategies and operations with universal principles on human rights, labor, environment, and anti-corruption, as well as take actions that advance societal goals. With 468% growth in brand value since 2020, Persistent is the fastest-growing IT services brand in 'Brand Finance India 100' 2025 Report.
www.persistent.com
Forward-looking and Cautionary Statements
For risks and uncertainties relating to forward-looking statements, please visit persistent.com/flcs
View original content:https://www.prnewswire.com/news-releases/persistent-and-kong-announce-strategic-partnership-to-help-enterprises-securely-move-ai-into-production-302781058.html
The Boat House, the #1 Bennington dealer in Wisconsin, brings its full-service Bennington program to Collier County as the brand's exclusive authorized dealer
, /PRNewswire/ -- The Boat House, a 5 Star Certified MRAA dealer group operating 10 locations across Southwest Florida and the Midwest, has been named the exclusive authorized dealer for Bennington Pontoon Boats in Collier County, Florida, effective July 1, 2026. The designation makes The Boat House the sole source for Bennington sales and factory-authorized service in the county, covering Naples, Marco Island, and the surrounding area. The announcement comes as Collier County cements its reputation as one of Southwest Florida's most affluent and fastest-growing communities, with new residential development and registered vessel counts both rising year over year since 2023. Inventory is arriving in phases beginning late June 2026, with additional models arriving through July.
The Boat House Naples, located at 8582 Radio Lane, serves as the company's Southwest Florida flagship and the exclusive authorized Bennington Pontoon sales and service center for Collier County, Florida. The facility spans 20,000+ square feet across 4.2 acres with eight extended indoor service bays. Call (239) 732-8050 or visit BoatHouseH2o.com Bennington is the #1 selling premium pontoon brand in North America and has earned the CSI Award for customer satisfaction for 24 consecutive years — every year since the award's founding. The brand is owned by Polaris Inc. (NYSE: PII) and offers an industry-leading lifetime structural warranty plus a 10-year bow-to-stern warranty on every new boat. The 2026 lineup spans five series and 16 to 30 feet in pontoon and tritoon configurations.
The Boat House Naples, located at 8582 Radio Lane, opened in October 2025 and spans more than 20,000 square feet across 4.2 acres, including eight extended indoor service bays. The facility serves as the company's flagship location for Southwest Florida and is now the designated service and sales center for Bennington in Collier County.
"Earning the exclusive Bennington authorization for Collier County is something we worked hard for, and we don't take the responsibility lightly. We've been the #1 Bennington dealer in Wisconsin for years, and we know what it takes to do this brand justice. Naples is one of the premier boating markets in the country, and Collier County buyers deserve access to the best premium pontoon on the water. We're ready to deliver that."
— Kevin Code, CEO, The Boat House
With two decades serving Southwest Florida, The Boat House Naples has built a reputation for exceptional service, backed by outstanding customer reviews and recognition from the Marine Retailers Association of the Americas (MRAA). The Boat House Naples holds the MRAA's 5 Star Certified Dealer designation and has been named a Great Dealership to Work For by the MRAA for the fourth consecutive year, an honor earned by scoring 90% or higher on the MRAA Employee Satisfaction Survey. Bennington is the latest addition to a lineup that already reflects the company's broader commitment to world-class marine retail across 10 locations and 250+ employees throughout Southwest Florida and the Midwest.
The Boat House Naples is now an authorized Bennington sales and service center, bringing the proven expertise of Wisconsin's #1 Bennington dealer to Southwest Florida. Through June 30, new service customers will receive free pickup and delivery plus a complimentary system check.
"The Boat House has built an outstanding reputation in Wisconsin through its unwavering commitment to customer satisfaction, operational excellence, and high-quality service — consistently demonstrating the standards the Bennington brand demands. We are confident they will bring that same integrity and proven track record to Collier County, delivering the exceptional experience customers expect and deserve from day one."
— Mark Skeen, Bennington Marine
Collier County's year-round navigable waterways, high concentration of waterfront properties, and affluent buyer base make it one of the strongest premium boating markets in Florida and one where The Boat House intends to build a long-term Bennington presence worthy of the market.
For more information, to browse available inventory, or to place a Bennington order, visit boathouseh2o.com/bennington-boats-for-sale or call The Boat House Naples directly at (239) 732-8050.
About The Boat House
The Boat House is a family-owned marine dealership group with more than 30 years in the industry and nearly two decades serving Southwest Florida. The company operates 10 dealership locations across Florida and the Midwest — including Naples, Cape Coral, and Port Charlotte, Florida; Johnsburg, Illinois; and six Wisconsin locations in Door County, Lake Country, Lake Geneva, Lauderdale Lakes, Three Lakes, and Whitewater — along with additional operations facilities and storage centers throughout the region. The Boat House offers new and used boat sales, service, storage, parts, pier and lift services, and a boat club. The company holds the MRAA's 5 Star Certified Dealer designation and is the #1 Bennington dealer in Wisconsin. Learn more at BoatHouseH2o.com.
About Bennington Marine
Bennington is North America's #1 selling premium pontoon brand and a subsidiary of Polaris Inc. (NYSE: PII). Bennington pontoons are built with an industry-leading lifetime structural warranty and a 10-year bow-to-stern warranty and have earned the CSI Award for customer satisfaction for 24 consecutive years. Learn more at BenningtonMarine.com.
The Boat House, the #1 Bennington dealer in Wisconsin, brings its full-service Bennington program to Collier County as the brand's exclusive authorized dealer
, /PRNewswire/ -- The Boat House, a 5 Star Certified MRAA dealer group operating 10 locations across Southwest Florida and the Midwest, has been named the exclusive authorized dealer for Bennington Pontoon Boats in Collier County, Florida, effective July 1, 2026. The designation makes The Boat House the sole source for Bennington sales and factory-authorized service in the county, covering Naples, Marco Island, and the surrounding area. The announcement comes as Collier County cements its reputation as one of Southwest Florida's most affluent and fastest-growing communities, with new residential development and registered vessel counts both rising year over year since 2023. Inventory is arriving in phases beginning late June 2026, with additional models arriving through July.
The Boat House is Collier County's exclusive Bennington dealer. Service open now. 2026 inventory arriving late June.
Bennington is the #1 selling premium pontoon brand in North America and has earned the CSI Award for customer satisfaction for 24 consecutive years — every year since the award's founding. The brand is owned by Polaris Inc. (NYSE: PII) and offers an industry-leading lifetime structural warranty plus a 10-year bow-to-stern warranty on every new boat. The 2026 lineup spans five series and 16 to 30 feet in pontoon and tritoon configurations.
The Boat House Naples, located at 8582 Radio Lane, opened in October 2025 and spans more than 20,000 square feet across 4.2 acres, including eight extended indoor service bays. The facility serves as the company's flagship location for Southwest Florida and is now the designated service and sales center for Bennington in Collier County.
"Earning the exclusive Bennington authorization for Collier County is something we worked hard for, and we don't take the responsibility lightly. We've been the #1 Bennington dealer in Wisconsin for years, and we know what it takes to do this brand justice. Naples is one of the premier boating markets in the country, and Collier County buyers deserve access to the best premium pontoon on the water. We're ready to deliver that."
— Kevin Code, CEO, The Boat House
With two decades serving Southwest Florida, The Boat House Naples has built a reputation for exceptional service, backed by outstanding customer reviews and recognition from the Marine Retailers Association of the Americas (MRAA). The Boat House Naples holds the MRAA's 5 Star Certified Dealer designation and has been named a Great Dealership to Work For by the MRAA for the fourth consecutive year, an honor earned by scoring 90% or higher on the MRAA Employee Satisfaction Survey. Bennington is the latest addition to a lineup that already reflects the company's broader commitment to world-class marine retail across 10 locations and 250+ employees throughout Southwest Florida and the Midwest.
The Boat House Naples is now an authorized Bennington sales and service center, bringing the proven expertise of Wisconsin's #1 Bennington dealer to Southwest Florida. Through June 30, new service customers will receive free pickup and delivery plus a complimentary system check.
"The Boat House has built an outstanding reputation in Wisconsin through its unwavering commitment to customer satisfaction, operational excellence, and high-quality service — consistently demonstrating the standards the Bennington brand demands. We are confident they will bring that same integrity and proven track record to Collier County, delivering the exceptional experience customers expect and deserve from day one."
— Mark Skeen, Bennington Marine
Collier County's year-round navigable waterways, high concentration of waterfront properties, and affluent buyer base make it one of the strongest premium boating markets in Florida and one where The Boat House intends to build a long-term Bennington presence worthy of the market.
For more information, to browse available inventory, or to place a Bennington order, visit boathouseh2o.com/bennington-boats-for-sale or call The Boat House Naples directly at (239) 732-8050.
About The Boat House
The Boat House is a family-owned marine dealership group with more than 30 years in the industry and nearly two decades serving Southwest Florida. The company operates 10 dealership locations across Florida and the Midwest — including Naples, Cape Coral, and Port Charlotte, Florida; Johnsburg, Illinois; and six Wisconsin locations in Door County, Lake Country, Lake Geneva, Lauderdale Lakes, Three Lakes, and Whitewater — along with additional operations facilities and storage centers throughout the region. The Boat House offers new and used boat sales, service, storage, parts, pier and lift services, and a boat club. The company holds the MRAA's 5 Star Certified Dealer designation and is the #1 Bennington dealer in Wisconsin. Learn more at BoatHouseH2o.com.
About Bennington Marine
Bennington is North America's #1 selling premium pontoon brand and a subsidiary of Polaris Inc. (NYSE: PII). Bennington pontoons are built with an industry-leading lifetime structural warranty and a 10-year bow-to-stern warranty and have earned the CSI Award for customer satisfaction for 24 consecutive years. Learn more at BenningtonMarine.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-boat-house-named-exclusive-bennington-pontoon-dealer-for-collier-county-florida-302781897.html
Polaris The Foundation for America's Public Lands and Polaris have joined forces; Award first round of grants to seven projects across four states
, /PRNewswire/ -- A new partnership is helping fund projects to improve off-road trails and riding areas across the United States. The Foundation for America's Public Lands, the official charitable partner of the Bureau of Land Management (BLM), and Polaris, a global leader in powersports, are providing grants to support off-highway vehicle (OHV) recreation access, safety and the riding experience on BLM lands.
The partnership will provide over $700,000 of impact to support OHV projects on BLM lands. The grants will be funded through a $350,000 donation from Polaris and will leverage a dollar-for-dollar match by the Foundation. Support includes funding new and additional signage, as well as trail maintenance and repairs to help support safety, access, and continued use of these OHV spaces.
The BLM manages some of the most iconic and beloved motorized recreation areas in the nation, with over 200 designated OHV recreation sites and millions of acres open to responsible motorized recreation. These are places where families, friends, and entire communities gather to spend time outdoors, connect, and build the kind of shared experiences that empower local economies and keep people coming back to ride.
"People are deeply connected to the areas they spend their days riding, and we know strong communities are at the heart of maintaining these spaces. Through our new partnership with the Foundation for America's Public Lands, we will invest alongside local partners to improve trails, promote responsible riding, and support the people who know these areas better than anyone, helping to keep these places thriving," said Mike Speetzen, Polaris CEO. "We are privileged to work alongside the Foundation, the Bureau of Land Management and local partners to help bring these important projects to life."
"America's public lands are powerful economic drivers and places where Americans can get outside to experience the Great Outdoors," said I Ling Thompson, Chief Executive Officer of the Foundation for America's Public Lands. "BLM lands offer countless opportunities for multiple use recreation, and we are thrilled to partner with Polaris to support local communities and bring much needed funding to these important projects."
The partnership officially kicked off over the weekend at North Reno Recreation Area's "Moon Rocks," the 19,000 acres of public land that includes the BLM's OHV area. Hundreds of volunteers gathered to participate in the Friends of Moon Rock's annual clean-up event at the beloved riding area. Moon Rocks is one of seven locations being awarded a grant as part of the Polaris & Foundation partnership. The Moon Rocks grant is supporting the installation of new portal signs that connect visitors with the site, along with barriers to assist in directing traffic to the main trail head.
"It is astounding to see all of these partners, including the Foundation, Polaris, and all of the volunteers coming together to enhance the Moon Rocks Recreation Area," said Kim Dow, Associate State Director of BLM Nevada. "Without their support and dedication, Moon Rocks would not be what it is today. It is a great demonstration of the Northern Nevada community's dedication and support for our public lands."
This partnership will also support the following six projects:
Cricket Mountains OHV Trail System (Utah): Riders will have clearer guidance across the entire trail system with a full signage overhaul, including new directional markers, trail maps, and wayfinding signs installed in partnership with the BLM Fillmore Field Office. Greater Three Peaks OHV Riding Area (Utah): About 4,800 feet of fencing around "the crater" will reduce safety hazards from dense informal routes and irregular terrain, making one of the area's most-used zones more accessible and rideable. Tusher Tunnel, Uranium Arch and Bartlett Alcove (Utah): Updated signage, parking improvements, and site maintenance across three BLM Moab locations will improve the visitor experience and keep these high-traffic areas in good shape for continued use. Fivemile Pass Recreation Area (Utah): Restroom repairs and new kiosks at seven staging areas will enhance amenities at Utah's most loved OHV areas, keeping it welcoming to all riders. Black Canyon Corridor (Arizona): 1,400 new waypoints and interpretive markers will make the corridor easier to navigate and more engaging to explore, with installation led by youth in alignment with the EXPLORE Act. Glendive Short Pines OHV Area (Montana): A shade structure and ADA concrete trail will complete a long-awaited facility, opening the area to visitors of all riding skill levels, all while providing Eastern Montana with a brand recreation destination. The priorities of Polaris and The Foundation's partnership include supporting OHV recreation, promoting safe and responsible off-road riding, enhancing the riding experience in and around the highest use recreation areas, and partnering with local communities on these projects. The Foundation's mission is to build strategic partnerships, generate private support, and help connect more people and communities to their public lands and waters. These grants and this partnership a part of Polaris' broader mission to encourage outdoor recreation and support the safety of its riders and the OHV community as a whole.
ABOUT THE FOUNDATION FOR AMERICA'S PUBLIC LANDS
As the official charitable partner of the Bureau of Land Management (BLM), the Foundation for America's Public Lands serves as a convener, partner, and fundraising catalyst to help ensure the health and stewardship of America's public lands and waters today, and for the future. To learn more, visit americaslands.org.
ABOUT POLARIS
As the global leader in powersports, Polaris Inc. (NYSE: PII) has been defining and redefining outdoor adventure since 1954. Polaris delivers industry-shaping off-road vehicles, snowmobiles, boats, military, quadricycles, and commercial transportation vehicles, along with an expansive portfolio of parts, garments, and accessories. Its lineup includes some of the most iconic brands in powersports including the RANGER, RZR, Polaris XPEDITION, Bennington pontoons, Slingshot, and more. Headquartered in Minnesota and serving customers in nearly 100 countries, Polaris continues to set the standard for performance, quality, and unmatched service. Explore more at www.polaris.com.
TORONTO, ON / ACCESS Newswire / June 8, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announced that Mexico's Secretary of Energy (Secretaría de Energía, "SENER"), and the Federal Electricity Commission (Comisión Federal de Electricidad, "CFE") have completed the first national competitive selection process under the CFE Mixed Development Program.
The process was launched through a Request for Proposals ("RfP") issued in February 2026, with submitted projects evaluated in accordance with the Guidelines for Mixed Development Programs published by SENER in January 2026. On June 5, 2026, CFE and SENER announced that the final award volume exceeded the original target, with approximately 8,000 MW of projects selected for advancement under the program.
As part of this award process, Polaris is pleased to announce that all three Polaris-owned projects submitted under the Mixed Development Program have been selected to advance to the final contract negotiation stage with CFE. These three projects represent approximately 250 megawatts ("MW") of solar energy generation capacity, together with over 180 MWh of Battery Energy Storage Systems ("BESS") located in strategically important energy regions across Mexico.
All three projects will now proceed toward the negotiation and execution of definitive project agreements, including power purchase arrangements ("PPAs") as well as shareholder and governance agreements. CFE has indicated that definitive agreements are expected to be executed by the end of July 2026. Once such agreements have been finalized, Polaris will provide more project specific details including estimated capital costs and construction timelines.
The Mixed Development Program represents the largest renewable energy and energy storage procurement initiative undertaken in Mexico. The program was established to facilitate strategic partnerships between CFE and private sector developers for the development, financing, construction, operation, and maintenance of new electricity generation and storage facilities throughout the country. The initiative forms a central component of Mexico's National Electricity System expansion strategy and seeks to accelerate the deployment of new generation capacity required to support growing industrial, commercial, and residential electricity demand. The program was designed to procure approximately 6,500 MW of new renewable generation and energy storage capacity by 2029. A key feature of the Mixed Development Program is the long-term contractual framework between CFE and successful private sector participants. The proposed 25-year power purchase and tolling arrangements are intended to provide stable and predictable revenue streams that support project financing and facilitate participation by domestic and international lenders, infrastructure funds, institutional investors, export credit agencies, and strategic partners.
For Polaris, the successful advancement of all three projects represents an important milestone in the Company's strategy to expand its renewable energy and energy storage platform in Mexico and further establish itself as a long-term partner in the country's energy transition and infrastructure development objectives.
CEO Marc Murnaghan commented "Mexico represents one of the most attractive growth markets within Polaris' portfolio. The successful selection of all three projects further strengthens the Company's long-term growth platform in a market characterized by sustained electricity demand growth, increasing industrial activity, and a continued need for new generation and storage infrastructure. Polaris continues to advance a pipeline of multiple additional project opportunities across Mexico that remain at various stages of evaluation, permitting, and commercial development."
Polaris remains committed to delivering long-term, sustainable energy solutions across Latin America and the Caribbean and looks forward to working with all stakeholders throughout the approval and implementation process.
About Polaris Renewable Energy Inc.
Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing and financially sound contributor to the energy transition.
The Company's portfolio includes a geothermal plant (~82 MW), four run-of river hydroelectric plants (~39 MW), three solar (photovoltaic) projects (~35 MW) and an onshore wind park (~26 MW).
For more information, contact:
Investor Relations
Polaris Renewable Energy Inc.
Phone: +1 647-245-7199
Email: [email protected]
Cautionary Statements
This press release contains certain "forward-looking information" which may include, but is not limited to, statements with respect to future events or future performance, the expected use of proceeds or rating(s) of any such issuance, the Company's acquisition and other investment plans, any benefits to the Company's financial or business performance. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. Such factors include, among others, the ability of the Company to satisfy any interest payments, which may be affected by such factors as general business, economic, competitive, political and social uncertainties; the actual results of current geothermal, solar and hydro energy production, development and/or exploration activities and the accuracy of probability simulations prepared to predict prospective geothermal resources; changes in project parameters as plans continue to be refined; possible variations of production rates; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the geothermal and hydro power industries; political instability or insurrection or war; labour force availability and turnover; delays in obtaining governmental approvals or in the completion of development or construction activities, or in the commencement of operations; the ability of the Company to continue as a going concern and general economic conditions, as well as those factors discussed in the section entitled "Risk Factors" in the Company's Annual Information Form. These factors should be considered carefully, and readers of this press release should not place undue reliance on forward-looking information.
Although the forward-looking information contained in this press release is based upon what management believes to be reasonable assumptions, there can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The information in this press release, including such forward-looking information, is made as of the date of this press release and, other than as required by applicable securities laws, Polaris assumes no obligation to update or revise such information to reflect new events or circumstances.
Sims Leads All-Polaris Podium, Followed by Wayne Matlock in Second and First-Year RZR Factory Racing Driver Ethan Groom in Third
Polaris Locks Out Top Nine at Baja 500, Including Top Six with RZR Pro R Factory Machines
, /PRNewswire/ -- Polaris Off Road continued its dominance in SCORE competition this past weekend, sweeping the UTV Overall podium and securing the top nine overall positions at the 57th SCORE Baja 500. Longtime Polaris racer Branden Sims delivered a calculated and consistent performance to earn the UTV Overall victory behind the wheel of his RZR Pro R Factory. Fellow Polaris racers Wayne Matlock and first-year RZR Factory Racing driver Ethan Groom completed the all-Polaris podium in second and third, respectively.
Branden Sims Captures the UTV Overall at the Baja 500 in his RZR Pro R Factory
Sims Leads All-Polaris Podium, Followed by Wayne Matlock in Second and First-Year RZR Factory Racing Driver Ethan Groom in Third The grueling 468-mile Baja 500 demanded patience, consistency, and smart decision-making, and Sims delivered all three. A former Baja 500 and Baja 1000 champion seeking his first SCORE victory since 2022, Sims started sixth on the grid and methodically worked his way through the field while avoiding costly mistakes. Running a disciplined race from start to finish, he maintained a strong pace and positioned himself within striking distance of the leaders throughout the day. When an opportunity emerged late in the race, Sims was perfectly poised to capitalize, taking over the front position and never looking back. He maintained his advantage through the closing miles to secure the overall victory, marking his first triumph in just his second race behind the wheel of the new RZR Pro R Factory.
"Today was incredible, and it feels so good to get back on top and earn a win," said Sims. "To come away with the overall victory against such a talented field is really special. My new RZR Pro R Factory was absolutely dialed in and performed flawlessly all day long. We had a smart race plan, maintained a strong pace, picked our lines carefully, and put ourselves in position to capitalize when it mattered most. This is only my second race in the car, but the confidence it gives me behind the wheel is unbelievable."
Matlock and Groom also delivered impressive drives through the field to complete the all-Polaris podium. Starting ninth and outside the top 10, respectively, both drivers put together patient and consistent drives, steadily gaining positions throughout the day to secure second- and third-place finishes, giving Polaris a clean sweep of the overall podium.
The Baja 500 further showcased the depth of Polaris' racing program, as Polaris racers claimed the top nine overall UTV finishing positions. Mitch Guthrie Jr. finished fourth, followed by Dallas Gonzalez in fifth, while Joe Terrana and co-driver Rodrigo Ampudia were sixth. Mike Cafro, Sebastian Marquez, and Kristen Matlock rounded out the top nine in seventh, eighth, and ninth, respectively.
Beyond the podium sweep and top-nine lockout, the race further demonstrated the unmatched capability of the RZR Pro R Factory platform. RZR Pro R Factory machines occupied the top six overall finishing positions, with Sims, Matlock, Groom, Mitch Guthrie Jr., Dallas Gonzalez, and Joe Terrana all piloting the championship-proven platform. Built to withstand the punishing terrain and relentless demands of Baja competition, the RZR Pro R Factory once again showcased the performance, durability, and reliability that have made it the benchmark in UTV desert racing.
"We couldn't be prouder of our Polaris racers and the entire team behind this program," said Alex Scheuerell, Polaris' Director of Off-Road Motorsports. "To sweep the podium at the Baja 500, secure the top nine overall UTV finishing positions, and see RZR Pro R Factory machines claim the top six spots overall is an incredible accomplishment. The RZR Pro R Factory continues to prove itself as the benchmark in off-road racing, delivering the performance, durability, and reliability needed to win in the toughest conditions. This achievement is a testament to the dedication, talent, and relentless effort of everyone involved in this program."
The RZR Factory Racing team will return stateside for the Best In The Desert Vegas to Reno, August 12-16, as it looks to build on its success in one of the longest and most challenging off-road races in the United States.
To learn more, please visit Polaris.com/RZR or join the conversation and follow on Facebook sm, Instagram sm, YouTube sm and Xsm.
About Polaris
As the global leader in powersports, Polaris Inc. (NYSE: PII) has been defining and redefining outdoor adventure since 1954. Polaris delivers industry-shaping off-road vehicles, snowmobiles, boats, military, quadricycles, and commercial transportation vehicles, along with an expansive portfolio of parts, garments, and accessories. Its lineup includes some of the most iconic brands in powersports including the RANGER, RZR, Polaris XPEDITION, Bennington pontoons, Slingshot, and more. Headquartered in Minnesota and serving customers in nearly 100 countries, Polaris continues to set the standard for performance, quality, and unmatched service. Explore more at www.polaris.com.
Vertex Pharmaceuticals (VRTX - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -4.9% over the past month versus the Zacks S&P 500 composite's +11% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has lost 1% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Vertex is expected to post earnings of $4.73 per share for the current quarter, representing a year-over-year change of +4.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -1.4%.
For the current fiscal year, the consensus earnings estimate of $19.02 points to a change of +3.4% from the prior year. Over the last 30 days, this estimate has changed -0.4%.
For the next fiscal year, the consensus earnings estimate of $21.23 indicates a change of +11.6% from what Vertex is expected to report a year ago. Over the past month, the estimate has changed -1.3%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Vertex is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Vertex, the consensus sales estimate of $3.2 billion for the current quarter points to a year-over-year change of +8%. The $13.02 billion and $14.21 billion estimates for the current and next fiscal years indicate changes of +8.5% and +9.1%, respectively.
Last Reported Results and Surprise HistoryVertex reported revenues of $2.99 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $4.47 for the same period compares with $4.06 a year ago.
Compared to the Zacks Consensus Estimate of $2.98 billion, the reported revenues represent a surprise of +0.19%. The EPS surprise was +5.67%.
Over the last four quarters, Vertex surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Vertex is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Vertex. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Key Takeaways Vertex posted $2.99 billion in Q1 sales, up 8%, driven by CF drugs and newer products Alyftrek and JournavxVRTX's Alyftrek reached $424.4 million in Q1 sales and topped $1 billion in cumulative global revenues.Vertex expects more than $500 million in 2026 non-CF revenues as Journavx and Casgevy expand access. Vertex Pharmaceuticals Incorporated’s (VRTX - Free Report) first-quarter 2026 results were decent as it beat estimates for earnings and sales.
The company’s total revenues of $2.99 billion rose 8% year over year, driven by higher sales of cystic fibrosis (CF) drugs Trikafta/Kaftrio and Alyftrek, as well as meaningful contributions from new non-CF products, Journavx and Casgevy. Vertex reiterated its full-year 2026 revenue guidance in the range of $12.95-$13.10 billion for 2026.
Investor focus was on the performance of Vertex’s newer drugs, Alyftrek, Journavx and Casgevy, which were launched in the past couple of years and hold the key to long-term growth.
Alyftrek is a once-a-day oral triple combination regimen for CF. Journavx is a novel non-opioid pain medicine (suzetrigine) and Vertex and partner CRISPR Therapeutics’ (CRSP - Free Report) Casgevy is a one-shot gene therapy approved for two blood disorders, sickle cell disease and transfusion-dependent beta-thalassemia.
Year to date, shares of Vertex have declined 6.3% compared with the industry’s decrease of 0.2%.
Image Source: Zacks Investment Research
Let’s dig deeper to understand how these new products performed in the first quarter and the company’s outlook for the same through the rest of the year.
VRTX’s Alyftrek Tops $1B Global Sales as Launch Gains PaceAlyftrek continues to outperform expectations and generated sales worth $424.4 million in the first quarter compared with $380.1 million in the fourth quarter. The rollout of Alyftrek in the United States and Europe is progressing well across all patient groups. The drug has now surpassed $1 billion in cumulative global revenues since its approval in the United States in late 2024 and in the EU in July 2025. Alyftrek’s once-daily dosing and improved sweat chloride profile continue to resonate with patients and doctors.
VRTX’s Casgevy, Journavx Contribute 25% of Revenue GrowthIn the first quarter, products from Vertex’s new non-CF disease areas, namely Casgevy and Journavx, drove approximately 25% of total product revenue growth, which was encouraging as Vertex’s dependence on just the CF franchise for revenues has been a growing concern. CF sales are also slightly slowing down.
Journavx (suzetrigine) generated $29 million in sales in the first quarter compared with $26.7 million in the fourth quarter. Prescription growth remains strong, although first-quarter revenues reflected some normal inventory destocking.
More than 350,000 prescriptions were written for Journavx across both hospital and retail settings in the quarter compared to approximately 550,000 in all of 2025, showing that uptake is accelerating. In 2026, Vertex expects Journavx prescriptions to triple compared to 550,000 written in 2025, supported by a larger commercial field force, wider payer coverage, and improving gross-to-net economics.
Journavx’s reimbursement trends are also improving. Coverage has expanded to about 240 million lives, supported by agreements with the three largest commercial pharmacy benefit managers. The company also secured its first major Medicare Part D coverage agreement, effective May 1. Discussions are continuing with the remaining major Medicare plans and regional payers, which could further expand access.
Vertex and partner CRISPR’s one-shot gene therapy, Casgevy’s sales were $42.9 million in the first quarter of 2026, down from $54.3 million recorded in the fourth quarter of 2025 due to quarter-to-quarter variability in Casgevy infusions.
Nonetheless, the launch of Casgevy is gaining traction across the United States, Europe and the Middle East, with more than 500 patients having started treatment since launch, hundreds completing initial cell collection, and many already reaching the stage where edited cells are ready for infusion.
Vertex is also making rapid progress in the drug’s access and reimbursement and secured a pricing agreement for Casgevy in Germany in the first quarter.
In 2026, Vertex expects continued quarter-to-quarter variability in Casgevy infusions, which the company expects will smooth out in 2027 and beyond.
While Alyftrek will be the key driver of Vertex’s total revenues in 2026, with Journavx and Casgevy gaining traction, Vertex is steadily broadening its growth base beyond CF. The company expects non-CF products to generate revenues of $500 million plus in 2026, representing year-over-year growth of around 185%, driven by growing Casgevy infusions and a meaningful ramp in Journavx prescriptions and revenues.
VRTX’s Zacks Rank & Stocks to ConsiderVertex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Agenus (AGEN - Free Report) and Amarin (AMRN - Free Report) , each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Agenus’ shares have risen 29.2% in the past year. Estimates for its 2026 earnings per share have increased from 54 cents to $1.30 over the past 60 days. Loss estimates for 2027 have narrowed from $1.91 per share to $1.52 per share.
Agenus’ earnings beat estimates in two of the trailing four quarters while missing in the other two, with the average surprise being 31.42%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $7.01 to $6.36 for 2026. During the same time, loss per share estimates for 2027 have narrowed from $5.50 to $4.64. In the past year, shares of AMRN have gained 42%.
Amarin’s earnings beat estimates in three of the trailing four quarters while missing in one, the average surprise being 50.02%.
Vertex Pharmaceuticals (VRTX - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -0.6% over the past month versus the Zacks S&P 500 composite's +4% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has lost 7.8% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Vertex is expected to post earnings of $4.74 per share, indicating a change of +4.9% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.3% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $19.11 points to a change of +3.9% from the prior year. Over the last 30 days, this estimate has changed +1.2%.
For the next fiscal year, the consensus earnings estimate of $21.24 indicates a change of +11.1% from what Vertex is expected to report a year ago. Over the past month, the estimate has changed -0.4%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Vertex is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Vertex, the consensus sales estimate for the current quarter of $3.2 billion indicates a year-over-year change of +8%. For the current and next fiscal years, $13.02 billion and $14.21 billion estimates indicate +8.5% and +9.1% changes, respectively.
Last Reported Results and Surprise HistoryVertex reported revenues of $2.99 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $4.47 for the same period compares with $4.06 a year ago.
Compared to the Zacks Consensus Estimate of $2.98 billion, the reported revenues represent a surprise of +0.19%. The EPS surprise was +5.67%.
Over the last four quarters, Vertex surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Vertex is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Vertex. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech innovators. Indeed, we’ve heard a lot about the promise of AI when applied to the field of biotechnology and healthcare.
From cancer treatments and curing a long list of diseases, perhaps there is no bigger win to be had from AI than within the health sector. Whether we’re talking about AI drug discovery, AI-driven diagnostics and screening, or even AI-powered hyper-personalized medicine, there’s a ton of promise as AI comes for biotech. With the rise of “dry labs” (think simulations over actually running experiments by mixing chemicals), perhaps the biotech landscape could shift in a profound way.
The biotech innovators are starting to look way too cheap Undoubtedly, the biotech scene is seen more as a less-predictable, perhaps more speculative playground for traders than a place where there’s a great deal of certainty. If AI delivers on its promise, perhaps biotech could become far more investable, which, in turn, could make some of the names worth heftier premiums.
For now, biological AI is in its very early innings, and it’s hard to know when the ChatGPT moment will come for the field. Either way, though, I still think the names are looking cheap these days, especially for investors looking for lower betas, solid growth, and underrated AI exposure.
In this piece, we’ll look at two biotech names that could be worth a closer look as they quietly adopt AI to help produce the next big blockbuster. I have no idea when the Mythos of biotech will arrive, but when it does, I think it’ll be tough to ignore the biotech innovators.
Vertex Pharmaceuticals Shares of Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) have done next to nothing in the past two years. The vicious moves in both directions have made the $111 billion biotech play more of a question mark than a name that’s a must-buy on weakness. While the name isn’t exactly an AI stock, the firm is putting machine learning to good use behind the scenes. Time will tell how much AI can help speed things up, but either way, the potential is there.
In the meantime, Vertex is under pressure following softer-than-expected launches of new drugs. The cystic fibrosis business might be firing on all cylinders, but beyond that, investors are wondering where the next big growth spurt will come from.
With a solid pipeline that could refuel growth in the coming year, perhaps Vertex will get its moment to break out. Until then, the stock looks like a cheap way —22.9 times forward price-to-earnings (P/E) — to punch a ticket to low-beta (0.30) growth.
Regeneron Regeneron (NASDAQ:REGN) stock has already crashed close to 48% from its 2024 high. The Fianlimab disappointment has weighed quite heavily, and as the firm invests considerable sums in its next big drug, questions linger as to whether the hefty R&D (around $6 billion guided for 2026) is going to turn investors away.
Though there’s no easy way out, there are notable catalysts coming up beyond oncology. With a packed pipeline and plenty of potential to get the pipeline moving faster at the hands of AI, I consider the name to be a great deal at 15.3 times trailing P/E. The 0.30 beta is quite low and should help shelter investors if the AI trade were to go through another one of its upsets.
